.jpg)
ISE ETF Ventures has partnered with Loncar Investments, Exchange Traded Concepts, and Amplify Development to launch the only exchange-traded fund (ETF) focused on cancer immunotherapy, the emergent biotechnology sector dedicated to activating the body’s immune system to treat the disease. The ETF successfully launched on October 14, 2015, on NASDAQ.
“We are pleased to be working with Loncar Investments and our other partners to launch this product and continue our commitment to developing ETFs that capture distinctive and emerging investment themes,” said Kris Monaco, Head of ISE ETF Ventures. “This launch provides investors with the ability to obtain wider exposure to an industry with the potential to reshape existing cancer treatments.”
The ETF tracks the Loncar Cancer Immunotherapy Index (index ticker: LCINDX), an index created by biotechnology investor Brad Loncar which holds a combination of established pharmaceutical firms and clinical stage biotechnology companies leading this alternative approach to cancer treatment. Bristol-Myers Squibb (ticker: BMY), Merck (ticker: MRK), Juno Therapeutics (ticker: JUNO), and Cellectis (ticker: CLLS) are four of the index’s thirty holdings.
“Cancer immunotherapy brings impressive innovation to the biotechnology sector, and its recent advancements demonstrate long-term growth potential,” said Brad Loncar, CEO of Loncar Investments. “We’re happy to be working with ISE ETF Ventures, as they have a strong track record of successful ETF launches across a range of unique investment themes.”
ISE ETF Ventures partners with issuers to create and bring innovative exchange-traded products to market through index creation, index licensing, venture financing, marketing, and sales support. Visit www.ise.com/etfventures for more information.
